Estudo de desenvolvimento de comprimidos de liberação imediata em associação dose fixa para o tratamento de filariose

Neglected diseases consist of a group of endemic diseases, together with the situation of poverty, poor living conditions and health inequities. Among the studies that indicate the therapeutic of the pharmaceutical inputs: ivermectin, albendazole and doxycycline in the treatment of filariasis. The objective of this work was to carry out a study of technological development of tablets in double doses of drugs and, in parallel, to develop and validate an analytical method, besides carrying out a preliminary study of stability by thermal analysis. The pre-calibration study was performed with a kind of thermal assay (differential exploratory and thermogravimetric calorimetry) and non-thermal (Fourier transform infrared spectroscopy, scanning electron microscopy and x-ray diffusion). The quantification and assay method was developed and validated by ultra-efficient liquid chromatography, in order to support the determination and dissolution. New biopharmacotechnical parameters were introduced in a total of new bench batches. The preliminary mechanical test was built on the Arrhenius triple in the isoconversional version of Ozawa-Flynn-Wall. The compatibility study showed that the drugs are more important among themselves and with most of the excipients tested. Surgery in the preparation of granulation and method of the production of disintegrating agent and binder type. After evaluation of biopharmacological parameters only F1, F2 and F4 were discontinued at disintegration time ≤30 min. Regarding the interference of the type of binder in the friability, an 8% starch paste showed a greater sensitivity to the others tested. Bids were approved in the assay and did not show dissolution profile higher than 80% without time of 30 min. No preliminary stability study. From the obtained results, one can conclude the knowledge of the physical-chemical properties of the drugs allows us a rational use during the development of new products, in order to guarantee a new structure with the parameters of quality control and stability well defined and thus, complementary drug therapies for the various pathologies.